06476831-E051-4D7F-B7B1-A9A3D1A60064
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.901445466491456
- age_years
- 39
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.526
- G2M_CHECKPOINT+0.526
- MYC_TARGETS_V2+0.444
- MYC_TARGETS_V1+0.411
- MITOTIC_SPINDLE+0.408
- CHOLESTEROL_HOMEOSTASIS+0.334
- WNT_BETA_CATENIN_SIGNALING+0.296
- DNA_REPAIR+0.292
- TGF_BETA_SIGNALING+0.246
- PROTEIN_SECRETION+0.234
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.469
- KRAS_SIGNALING_DN-0.393
- MYOGENESIS-0.378
- HYPOXIA-0.307
- COAGULATION-0.298
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.288
- OXIDATIVE_PHOSPHORYLATION-0.273
- ESTROGEN_RESPONSE_LATE-0.256
- SPERMATOGENESIS-0.227
- XENOBIOTIC_METABOLISM-0.223
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EED16435-CBED-4143-B5BA-C5C7C8510C3A | — | — | 0.918 |
| 2 | EDABB4DE-6443-4EA2-B64A-9C492D3F5A2C | — | — | 0.918 |
| 3 | FB361DEF-9354-4467-9FF0-BF21F642A654 | — | — | 0.906 |
| 4 | 86379365-5FD2-4655-8B3C-B8E0EE25EE92 | — | — | 0.906 |
| 5 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.893 |
| 6 | 2DA298A9-AB20-4F9D-B83F-C7FC0679F889 | — | — | 0.889 |
| 7 | SRR934823 | — | — | 0.888 |
| 8 | SRR934847 | — | — | 0.888 |
| 9 | CB9E4206-E2F7-49EA-8FB2-E69E5BB3B018 | — | — | 0.886 |
| 10 | 19EBA5E0-D299-4166-834A-256294572121 | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.526 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.526 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.444 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.411 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.408 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.334 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.296 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.292 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.246 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.234 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.234 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.227 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.165 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.135 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.101 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.052 | Inavolisib | — uncovered |